Targeting LAG-3 restores CD8+ T cell effector function through CD94/NKG2-Qa-1b signaling

Zhiqiang Wang , Mingzhu Yin , Ge Lou

MEDCOMM - Oncology ›› 2024, Vol. 3 ›› Issue (4) : e70003

PDF
MEDCOMM - Oncology ›› 2024, Vol. 3 ›› Issue (4) : e70003 DOI: 10.1002/mog2.70003
HIGHLIGHT

Targeting LAG-3 restores CD8+ T cell effector function through CD94/NKG2-Qa-1b signaling

Author information +
History +
PDF

Cite this article

Download citation ▾
Zhiqiang Wang, Mingzhu Yin, Ge Lou. Targeting LAG-3 restores CD8+ T cell effector function through CD94/NKG2-Qa-1b signaling. MEDCOMM - Oncology, 2024, 3(4): e70003 DOI:10.1002/mog2.70003

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

NgiowSF, ManneS, HuangYJ, et al. LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell. 2024;187(16):4336-4354.e19.

[2]

KhanO, GilesJR, McDonaldS, et al. TOX transcriptionally and epigenetically programs CD8+T cell exhaustion. Nature. 2019;571(7764):211-218.

[3]

KureshiCT, DouganM, DouganSK. Anti-LAG-3 boosts CD8 T cell effector function. Cell. 2024;187(16):4144-4146.

[4]

AndrewsLP, ButlerSC, CuiJ, et al. LAG-3 and PD-1 synergize on CD8+T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity. Cell. 2024;187(16):4355-4372.e22.

[5]

CilloAR, Cardello C, ShanF, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+T cells to promote antitumor immunity. Cell. 2024;187(16):4373-4388.e15.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).

AI Summary AI Mindmap
PDF

138

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/